Schering's diagnostic sales down 6%:
This article was originally published in Clinica
Executive Summary
German company Schering's contrast media sales fell 6% to DM 1,194 million ($838 million) in the first nine months of 1995. The company blames the strong mark together with the withdrawal of its contrast medium, Isovist 280 (see Clinica No 675, p 9). Schering feels that although sales will be lost through the product withdrawal, this may be partially offset by increased sales of other Schering contrast agents. Net profits were down 18% to DM 172 million and total group sales fell 2% to DM 3,499 million. Analysts predict that on current sales performance and forecasts, results for 1996 will not improve on those for 1994.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.